Buc, France – September 29, 2020 – GE Healthcare announces the launch of the AI DReAM project, a consortium that gathers French SMEs, start-ups, research labs and clinical centers to facilitate the development of AI in medical imaging. Supported with €13 million by the “Investments for the Future” program (PIA), led by the French General... Read more
SAFE AND RELIABLE SAMPLE PRESERVATION AT AMBIENT TEMPERATURE FOR IVD APPLICATIONS Zymo Research was granted the CE IVD mark for its DNA/RNA Shield™ reagent and collection devices. IRVINE, Calif., (Sept. 25, 2020) — Zymo Research announced that three of its DNA/RNA Shield™ collection devices: 1) DNA/RNA Shield™ collection tube w/ swab, 2) DNA/RNA Shield™ Saliva/Sputum Collection Kit, and 3) DNA/RNA Shield™ Fecal Collection... Read more
NGS-enabled platform tracks infection clusters for contact tracing and monitors emerging mutations, combining once separate aspects of screening and genomic surveillance SAN CARLOS, CALIF. (PRWEB) SEPTEMBER 24, 2020 Clear Labs, providers of the only fully automated and intelligent next-generation sequencing (NGS) in vitro diagnostic (IVD) platform, today announced that the U.S. Food and Drug Administration (FDA) has... Read more
Thermo Fisher Scientific Introduces Oncomine Clinical Research Grant Program to Support Oncology and Reproductive Health Studies CARLSBAD, Calif., Sept. 23, 2020 /PRNewswire/ — Thermo Fisher Scientific today introduced the Oncomine Clinical Research Grant Program to support clinical research projects in oncology and reproductive health. The program aims to provide support for high-quality molecular profiling studies... Read more
EMPACTA is the first global phase III trial to show efficacy with Actemra/RoActemra in COVID-19 associated pneumonia and the first with a focus on enrolling largely underserved and minority patients There was no statistical difference in mortality between patients who received Actemra/RoActemra or placebo Roche plans to share these results with health authorities, including the... Read more
MINNEAPOLIS, Sept. 17, 2020 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) and QIAGEN N.V. today announced the expansion and extension of a non-exclusive partnership to co-market exosome technology to existing and potential biopharma partners as well as the joint development of new exosome based products. The agreement grants QIAGEN a non-exclusive development license to Bio-Techne’s exosome... Read more
Acquisition of the approval for marketing the Novel Coronavirus (SARS-CoV-2) Detection Reagent Kit as an In Vitro Diagnostic Product Read more
Hilden, Germany and Ann Arbor, Michigan, September 17, 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the acquisition of the remaining 80.1% of diagnostics instruments company NeuMoDx Molecular, Inc. for $248 million in cash. The move rounds out QIAGEN’s portfolio of automated molecular testing solutions based on the proven PCR technology.... Read more
Fill Up Your Sanger Sequencers & Test to Capacity ANN ARBOR, Mich, (September 29th, 2020) Swift Biosciences, a leader in Next-Generation Sequencing Manufacturing & Technology and BillionToOne, a precision diagnostics company today announced that Swift Bioscience will be the exclusive distributor of BillionToOne’s RNA extraction-free, Emergency Use Authorization (EUA) COVID-19 Test Kit for high capacity... Read more